Real-World Treatment Switching and Sequencing to Next Line of Therapy of Zanubrutinib, Acalabrutinib, and Ibrutinib in Chronic/Small Lymphocytic Leukemia (CLL/SLL)

被引：0

作者：

Pinilla-Ibarz, Javier ^{[1
]}

Xue, Mei ^{[2
]}

Wu, Elizabeth ^{[3
]}

Esselman, Kaitlyn ^{[3
]}

Furnback, Wesley ^{[3
]}

Challagulla, Swetha ^{[2
]}

Yang, Keri ^{[2
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] BeiGene USA Inc, San Mateo, CA USA

[3] Real Chem, New York, NY USA

来源：

关键词：

CLL; chronic lymphocytic leukemia; ibrutinib; zanubrutinib; acalabrutinib; treatment switching;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CLL-534

引用

页码：S358 / S359

页数：2